Alternatives to ketamine in depression: state-of-the-art and future perspectives

Pharmacological treatments in major depressive disorder (MDD) have historically focused on monoaminergic modulation. However, this strategy has limitations, such as a significant delay in the onset of therapeutic action and a large proportion of patients demonstrating persistent, treatment-resistant depression. There is a real need for novel rapid-acting antidepressants with alternative mechanisms of action